Click Here For COVID-19 (Coronavirus) Studies

RecruitMe Clinical Trial

A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Pediatric and Adolescent Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ZUMA-4)
Study Evaluating KTE-C19 in Adolescent Subjects With Acute Lymphoblastic Leukemia or B-Cell Non-Hodgkin Lymphoma (ZUMA-4)
Sponsor:KITE Pharma
Enrolling:Male and Female Patients
Study Length:15 Years
Clinic Visits:40
Age Range:Between 2 and 21 years old
IRB Number:AAAS3695
U.S. Government ID:NCT02625480
Contact: Jean Sosna, RN: 212-305-2050 / js4403@cumc.columbia.edu
Additional Study Information:

The main purpose of this research study is to determine if the experimental product, KTE-C19, when administered after you receive 3 days of chemotherapy, is safe and effective in treating your leukemia or non-Hodgkin lymphoma.

Do You Qualify?
Do you have leukemia or Non-Hodgkin Lymphoma?YesNo
Do you have measurable disease in the Bone Marrow?YesNo
Is CD19 tumor expression on blasts after your most recent completion of therapy?YesNo
Do you have any fungal, bacterial, viral or other infection that is uncontrolled or requiring IV microbials?YesNo
Are you taking corticosteroid therapy at a does of or = to 0.7 mg/kg/day?YesNo
Submit
Cancel
Investigator
Prakash Satwani, MD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Jean Sosna, RN
Email: js4403@cumc.columbia.edu
Phone: 212-305-2050